KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Neurosurgery / 2019 / Cilt: 29 - Sayı: 5

Microsatellite Instability in Glioblastoma: Is It Really Relevant in Tumor Prognosis?

Merih TEPEOĞLU
Pelin BÖRCEK
Özlem ÖZEN
Nur ALTINÖRS
Sayfa
778–784
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The overall median survival was 30.65 ± 5.1 and 10.71 ± 5.2 months in the MSS GBM and MSI GBM groups,respectively (p=0.059).CONCLUSION: The results of this study showed no significant relationships between MMR protein expression and recurrence ratesor overall survival in patients with GBM.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:AIM: To evaluate the frequency and prognostic significance of microsatellite instability (MSI) in patients with glioblastoma (GBM), animmunohistochemical analysis of mismatch repair (MMR) proteins was performed.MATERIAL and METHODS: A total of 71 patients with GBM who underwent surgery between 2011 and 2019, were included inthe study.
📊
Temel Bulgular & Veri:MMR protein expression was examined using immunohistochemistical analysis of tumor tissue samples; the associationbetween the MMR status and clinicopathological findings was evaluated.RESULTS: Immunohistochemical analysis revealed expressions of MLH1, MSH2, MSH6, and PMS2 proteins in 67 (94.4%), 65(91.5%), 67 (94.4%), and 64 (90.1%) patients, respectively.
💡
Sonuç & Katkı:The overall median survival was 30.65 ± 5.1 and 10.71 ± 5.2 months in the MSS GBM and MSI GBM groups,respectively (p=0.059).CONCLUSION: The results of this study showed no significant relationships between MMR protein expression and recurrence ratesor overall survival in patients with GBM.
🔬Tür:Araştırma Makalesi
📍Kapsam:2011 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

AIM: To evaluate the frequency and prognostic significance of microsatellite instability (MSI) in patients with glioblastoma (GBM), animmunohistochemical analysis of mismatch repair (MMR) proteins was performed.MATERIAL and METHODS: A total of 71 patients with GBM who underwent surgery between 2011 and 2019, were included inthe study. MMR protein expression was examined using immunohistochemistical analysis of tumor tissue samples; the associationbetween the MMR status and clinicopathological findings was evaluated.RESULTS: Immunohistochemical analysis revealed expressions of MLH1, MSH2, MSH6, and PMS2 proteins in 67 (94.4%), 65(91.5%), 67 (94.4%), and 64 (90.1%) patients, respectively. Among the 71 patients, 64 (90.1%) expressing all MMR proteins wereconsidered microsatellite stable (MSS), and 7 (9.9%) patients showing loss of at least one of the MMR proteins were consideredto show MSI. Tumor recurrence was noted in 25 (39.1%) patients in the MSS GBM group, and 4 (57.1%) patients in the MSI GBMgroup (p=0.433). The overall median survival was 30.65 ± 5.1 and 10.71 ± 5.2 months in the MSS GBM and MSI GBM groups,respectively (p=0.059).CONCLUSION: The results of this study showed no significant relationships between MMR protein expression and recurrence ratesor overall survival in patients with GBM.

🔖

Bu Makaleye Atıf Yap

TEPEOĞLU, M., BÖRCEK, P., ÖZEN, Ö., ALTINÖRS, N. (2019). Microsatellite Instability in Glioblastoma: Is It Really Relevant in Tumor Prognosis?. Turkish Neurosurgery, Cilt: 29 - Sayı: 5, 778–784. https://ajindex.com/articles/405297

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, Chadwick RB, Kääriäinen H, Eskelinen M, Järvinen H, Mecklin JP, de la Chapelle A: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338: 1481-1487, 1998 2. Aldape K, Zadeh G, Mansouri S, Reifenberger G, Deimling A: Glioblastoma: Pathology, molecular mechanisms and markers. Acta Neuropathol 129:829-848, 2015 3. Baretti M, Le DT: DNA mismatch repair in cancer. Pharmacology and Therapeutics 189:45-62, 2018 4. Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ: Landscape of microsatellite instability across 39 cancer types. JCO Precision Oncology 1:1-15, 2017 5. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN: Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13:2038-2045, 2017 6. Chen W, Swanson BJ, Frankel WL: Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. Diagn Pathol 12:1-12, 2017 7. Cortes-Ciriano I, Lee S, Park WY, Kim TM, Park PJ: A molecular portrait of microsatellite instability across multiple cancers. Nat Commun 8:1-12, 2017 8. Dams E, van de Kelft EJZ, Martin JJ, Verlooy J, Willems PJ: Instability of microsatellites in human gliomas. Cancer Research 55:1547-1549,1995 9. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler M, Weller M, Reifenberger G, Tonn JC: Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129:659-670, 2011 10. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038,1993 11. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeros I, de La Chapelle A: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Eng J Med 352:1851-1860, 2005 12. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011 13. Hause RJ, Pritchard CC, Shendure J, Salipante SJ: Classification and characterization of microsatellite